Sepsis is not a monolithic condition. The failure of more than 100 immunomodulatory drug trials is likely because they treated all patients the same. The future of sepsis treatment mirrors oncology: subtyping patients based on their specific inflammatory profile to match them with a targeted therapy.
Early researchers were overwhelmed by the massive, chaotic changes in gene expression in sepsis patients, terming it a "genomic storm." Inflammatics' founders viewed this complexity not as an obstacle but as a rich dataset. By applying advanced computational analysis, they identified specific, interpretable signals for diagnosis and prognosis.
The modern definition of sepsis is not "blood poisoning" but a dysregulated host response. The immune system's inflammatory reaction spirals out of control, causing organ damage long after the initial infection is gone. In fact, fewer than half of sepsis patients have a detectable infection in their bloodstream.
Inflammatics initially tried to license its technology but was rejected by major diagnostic firms. The pitch—to build new capabilities and a new platform to displace their own multi-billion dollar microbiology tests—was a classic innovator's dilemma. This refusal by incumbents to disrupt themselves forced the founders to start their own company.
Modern critical care for sepsis only treats the consequences of the disease—organ failure, low blood pressure—with supportive measures like ventilators and IV fluids. There are zero approved therapies that actually treat the underlying root cause: the out-of-control immune response that is actively damaging the patient's body.
Even for common conditions like pneumonia, current diagnostic methods like sputum and blood cultures fail to identify a bacterial cause in 60% of cases. This diagnostic gap leads to clinical guesswork, resulting in dangerous under-treatment. In one study, one in eight patients with a bacterial infection was sent home from the ER without antibiotics.